Keywords
arterial hypertension
, galectin-3
p-selectin
growth differentiation factor 15
How to Cite
Abstract
The aim of this study was to determine the plasma levels of Galectin-3, P-selectin and GDF-15 in patients with arterial hypertension and type 2 diabetes mellitus. GDF-15 levels were significantly higher in patients with T2DM. Our findings indicate significant association between Galectin-3 and GDF-15 in patients with arterial hypertension, which shows the relationship between various pathogenic components of the inflammatory process.References
Pant S., Deshmukh A., Gurumurthy G.S. et al. (2014). Inflammation and Atherosclerosis-Revisited. J. Cardiovasc. Pharmacol. Ther. 19 (2): 170–178.
Townsend N., Wilson L., Bhatnagar P. et al. (2016). Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. Aug 14. 7,37 (42): 3232–3245.
Taylor K.S. (2013). All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. Aug, 36 (8): 2366–2371.
Krintus M.1., Kozinski M., Kubica J., Sypniewska G. (2014). Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit. Rev. Clin. Lab. Sci. Oct, 51 (5): 263–279.
2013 ESH/ESC Guidelines for the management of arterial hypertension. J. Hypertension. 31: 1281–1357.
Gehlken C., Suthahar N., Meijers W.C., de Boer R.A. (2018). Galectin-3 in Heart Failure: An Update of the Last 3 Years. Heart Fail Clin. Jan, 14 (1): 75–92.
Juan Wang, Guo-Juan Tan, Li-Na Han et al. (2017). Novel biomarkers for cardiovascular risk prediction. J. Geriatr. Cardiol. Feb, 14 (2): 135–150.